Champions Oncology (CSBR) Income from Non-Controlling Interests (2025)
Champions Oncology (CSBR) posted quarterly Income from Non-Controlling Interests of -$31000.0 for Q4 2025, down 3.33% quarter-over-quarter from -$30000.0 in Q3 2025.
Champions Oncology (CSBR) Income from Non-Controlling Interests (2025) Analysis & Trends
Champions Oncology's Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at -$31000.0 for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -31,000.00 |
| Jul 31, 2025 | -30,000.00 |